Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study

被引:814
作者
Friis-Moller, N [1 ]
Weber, R
Reiss, P
Thiébaut, R
Kirk, O
Monforte, AD
Pradier, C
Morfeldt, L
Mateu, S
Law, M
El-Sadr, W
De Wit, S
Sabin, CA
Phillips, AN
Lundgren, JD
机构
[1] Hvidovre Univ Hosp, Copenhagen HIV Programme, Sect 044, DAD Coordinating Ctr, DK-2650 Copenhagen, Denmark
[2] Univ Zurich Hosp, Div Infect Dis, Swiss HIV Cohort Study SHCS, CH-8091 Zurich, Switzerland
[3] Univ Zurich Hosp, Hosp Epidemiol, CH-8091 Zurich, Switzerland
[4] Univ Amsterdam, Acad Med Ctr, ATHENA, Dept Med & Infect Dis, NL-1105 AZ Amsterdam, Netherlands
[5] Bordeaux Univ Hosp, Aquitaine, Inst Sante Publ Epidemiol & Dev, Inserm U330, Bordeaux, France
[6] Hvidovre Univ Hosp, Copenhagen HIV Programme, EuroSIDA, DK-2650 Copenhagen, Denmark
[7] Univ Milan, L Sacco Hosp Vialba, ICONA, Dept Infect Dis, Milan, Italy
[8] CHU Nice Hop Archet, Serv Malad Infect & Trop & Med Interne, Nice, France
[9] Karolinska Hosp, Dept Infect Dis, S-10401 Stockholm, Sweden
[10] Autonomous Univ Barcelona, Dept Clin Pharmacol & Therapeut, BASS, Barcelona, Spain
[11] AHOD, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[12] Columbia Univ, Sch Publ Hlth, Div Epidemiol, CPCRA, New York, NY USA
[13] CHU St Pierre Hosp, Dept Infect Dis, Brussels, Belgium
[14] UCL Royal Free & Univ Coll, Royal Free Ctr HIV Med, London, England
[15] UCL Royal Free & Univ Coll, Dept Primary Care & Populat Sci, London, England
关键词
antiretroviral therapy; cardiovascular disease; adverse effects; cohort study; hyperlipidaemia; prevalence; risk factors;
D O I
10.1097/00002030-200305230-00010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease, and use of antiretroviral therapies. Design: Baseline data from 17 852 subjects enrolled in DAD, a prospective multinational cohort study initiated in 1999. Methods: Cross-sectional analyses of CVD risk factors at baseline. The data collected includes data on demographic variables, cigarette smoking, diabetes mellitus, hypertension, dyslipidaemia, body mass index, stage of HIV infection, antiretroviral therapy. Results: Almost 25% of the study population were at an age where there is an,appreciable risk of CVD, with those receiving a protease inhibitor (PI) and/or non-nucleoside reverse transcriptase inhibitor (NNRTI) tending to be older. 1.4% had a previous history of CVD and 51.5% were cigarette smokers. Increased prevalence of elevated total cholesterol (greater than or equal to 6.2 mmol/l) was observed among subjects receiving an NNRTI but no PI [odds ratio (OR), 1.79; 95% confidence interval (Cl), 1.45-2.22], PI but no NNRTI (OR, 2.35; 95% Cl, 1.92-2.87), or NNRTI + PI (OR, 5.48; 95% Cl, 4.34-6.91) compared to the prevalence among antiretroviral therapy (ART)-naive subjects. Subjects who have discontinued ART as well as subjects receiving nucleoside reverse transcriptase inhibitors had similar cholesterol levels to treatment-naive subjects. Higher CD4 cell count, lower plasma HIV RNA levels, clinical signs of lipodystrophy, longer exposure times to NNRTI and Pl, and older age were all also associated with elevated total cholesterol level. Conclusion: HIV-infected persons exhibit multiple known risk factors for CVD. Of specific concern is the fact that use of the NNRTI and PI drug classes (alone and especially in combination), particularly among older subjects with normalized CD4 cell counts and suppressed HIV replication, was associated with a lipid profile known to increase the risk of coronary heart disease. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:1179 / 1193
页数:15
相关论文
共 69 条
[1]  
Australian HIV Observational Database, 2002, HIV Med, V3, P28
[2]  
BECKER S, 2001, 8 C RETR OPP INF CHI
[3]   Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors [J].
Behrens, G ;
Dejam, A ;
Schmidt, H ;
Balks, HJ ;
Brabant, G ;
Körner, T ;
Stoll, M ;
Schmidt, RE .
AIDS, 1999, 13 (10) :F63-F70
[4]  
BHIVA Writing Committee, 2000, HIV Med, V1, P76
[5]  
BOZZETTE SA, 2002, 9 C RETR OPP INF SEA
[6]   Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].
Carpenter, CCJ ;
Cooper, DA ;
Fischl, MA ;
Gatell, JM ;
Gazzard, BG ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schechter, M ;
Schooley, RT ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390
[7]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[8]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[9]   Adverse effects of antiretroviral therapy [J].
Carr, A ;
Cooper, DA .
LANCET, 2000, 356 (9239) :1423-1430
[10]  
CARR A, 2002, 9 C RETR OPP INF SEA